2025 | magAssist: Advancing Innovation Through Resilience, Staying True to Our Mission

In 2025, magAssist achieved a pivotal transition—from a company driven by single-point technological breakthroughs to an internationally recognized platform-based Mechanical Circulatory Support (MCS) innovator. Guided by our enduring mission of "Technology in Service of Life," we continue to bring domestically developed medical innovations from the laboratory to broad clinical adoption, translating engineering progress into real-world patient impact.

I. Recognized by the Times: Innovation Driving Sustainable Growth

Throughout 2025, magAssist's innovation capabilities received extensive recognition from both governmental and industry authorities. Founder and CEO, Dr. Po-Lin Xu was invited to attend the national commemorative ceremony in Beijing—an honor that reflects not only individual achievement, but also national acknowledgment of breakthroughs in domestically developed advanced life-support technologies and tangible progress toward technological self-reliance.

Multiple authoritative recognitions were awarded across national, regional, industry, and international levels:

National & Regional Recognition

• Selected for five consecutive years as a Jiangsu Province Potential Unicorn Enterprise

• Certified as a National High-Tech Enterprise

• Recipient of the 4th Jiangsu Zifeng Award – Technology Innovation Enterprise

• Named among the Top Ten Scientific and Technological Advances in Jiangsu's Biopharmaceutical Sector

• Awarded 2025 Suzhou Top Ten Industrial Technology Achievements

Industry Recognition

• Honored as one of CCI's Ten Most Innovative Enterprises (10th Anniversary Edition)

• Ranked for the fourth time on the Future Healthcare Top 100 list, establishing magAssist as a benchmark in China's life-support device sector

International Recognition

• Shortlisted for the 2025 Prix Galien USA – Best Start-Up

• Selected by Fortune magazine as one of 23 Global Healthcare Companies to Watch, bringing Chinese MCS innovation to the global stage

In parallel, the company's core R&D team was recognized as a Jiangsu Province Outstanding Innovation Team, reflecting strong multidisciplinary collaboration and sustained technological execution.

II. A Global Voice: Advancing Chinese Innovation Through Science

In 2025, magAssist actively engaged with the global MCS community through academic exchange, reinforcing its evolution from a single-device developer to a platform-based MCS enterprise.

Key academic milestones included:

• At TCT 2025, NyokAssist® was selected for Late-Breaking Clinical Science, where results from the SAVE-PCI multicenter clinical trial were presented—marking a milestone for China-originated MCS innovation.

• Active participation in leading international conferences such as ISMCS and ISHLT, where magAssist systematically presented its multi-device platform strategy.

• Hosting investigator meetings involving experts from China and the United States, supporting alignment with international clinical and regulatory standards.

Domestically, magAssist hosted the Short- and Mid-Term Circulatory Support Forum, focusing on real-world case discussions and clinical experience sharing, contributing to the standardization and broader adoption of MCS therapies in China.

III. Innovation for Accessibility: Technology in Service of Patients

The ultimate purpose of innovation is patient benefit. In 2025, magAssist advanced medical accessibility through coordinated progress in technology iteration, product deployment, and reimbursement inclusion. The company's three core product lines entered a phase of scaled clinical application, expanding access to life-saving technologies.

Product progress highlights:

• MoyoAssist® Extra VAD: Expanded clinical indications and increased market adoption

• BreathMo® ECMO System: Completed clinical studies in China and entered the regulatory review phase

• NyokAssist® pVAD: Completed clinical trials in China and submitted for U.S. EFS, advancing a dual-track China–U.S. development strategy

Notably, the unified control platform supporting both VAD and ECMO indications received regulatory approval, validating the platform-based, modular development strategy from both clinical and regulatory perspectives.

Clinical value has been consistently demonstrated. The 9Fr collapsible pVAD design has shown strong adaptability to complex vascular anatomies, reduced complication risks, and reliable support in high-risk procedures, building trust through real-world evidence. Meanwhile, MoyoAssist® consumables were included in the Jiangsu Province and Suzhou City reimbursement catalogs, reducing patient financial burden and improving treatment accessibility. These achievements culminated in MoyoAssist® receiving the 2025 Suzhou Top Ten Industrial Technology Achievement award.

IV. Where Technology Meets Life: Every Patient Matters

Beyond milestones and awards, the most meaningful measure of success is patient survival and recovery. The following anonymized cases illustrate magAssist's commitment to Technology in Service of Life.

Case 1: Sustaining Life in a Midnight Emergency

 A 78-year-old patient presented with acute myocardial infarction complicated by cardiogenic shock. MoyoAssist® was urgently deployed, providing stable circulatory support for 72 hours and enabling definitive treatment. As vital signs stabilized, clinicians remarked, "The patient is back." The patient has since recovered and been discharged.

Case 2: A Safety Net During High-Risk Intervention

 A 52-year-old patient undergoing complex high-risk PCI faced significant hemodynamic instability risk. NyokAssist® provided continuous intra-procedural support, with its 9Fr collapsible design accommodating challenging vascular anatomy. The lead operator noted: "With this support, we can safely tackle the most complex lesions—this device protects both the patient and the clinical team."

Voices from the Front Line

 "One critically ill patient survived the most dangerous four days with MoyoAssist®. When the device was removed, the family said, ‘Thank you—for the care, and for this life-saving device.’ That is the greatest affirmation of our work."

V. Built Together: A Culture of Collaboration

Every achievement and every successful rescue reflects collective effort. At magAssist, progress is driven by cross-functional collaboration and shared responsibility across the organization.

The company continues to strengthen its long-term competitive foundation:

Intellectual Property:

• Successful legal protection of trade secrets

• Over 400 patent applications to date (approximately 200 filed in the past two years), covering core structural designs and platform control systems

• Ongoing expansion of IP in major U.S. and European markets

Organizational Capability:

• Fully established R&D, quality, and regulatory systems

• Formation of a U.S.-based team, enhancing global operational readiness

Looking Ahead to 2026: Advancing Access, Together

From national recognition to bedside recovery; from iterative engineering to the moment a clinician says "the patient is back"—magAssist remains firmly committed to its mission.

We may never meet every patient whose life has been touched by our technology, but their futures—and the relief of their families—are inseparable from the work of every magAssist team member.

With gratitude to clinical partners, collaborators, investors, and patients, magAssist enters 2026 with renewed focus: advancing independent innovation, strengthening core technologies, and expanding access to life-saving MCS solutions—so that more patients, in more places, can benefit from reliable and accessible circulatory support.